Dominik Heinzmann
Roche (Switzerland)(CH)Roche (Estonia)(EE)
Publications by Year
Research Areas
HER2/EGFR in Cancer Research, Breast Cancer Treatment Studies, Monoclonal and Polyclonal Antibodies Research, Statistical Methods in Clinical Trials, Cancer Treatment and Pharmacology
Most-Cited Works
- → 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial(2013)500 cited
- → Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort(2014)488 cited
- → Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial(2012)341 cited
- → Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti–Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer(2023)93 cited
- → HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up(2016)78 cited
- → Population pharmacokinetic and exposure–response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer(2015)74 cited
- → Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer(2019)71 cited
- → An interactive map to assess the potential spread of Lymnaea truncatula and the free-living stages of Fasciola hepatica in Switzerland(2008)67 cited
- → Clinical Pharmacokinetics of Vemurafenib(2017)59 cited
- → Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2–Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti–Human Epidermal Growth Factor Receptor 2 Therapy(2023)54 cited